The Centers for Medicare and Medicaid Services’ coverage policy on erythroprotein has huge commercial implications for producers Amgen and J&J. It is also a wake-up call for the rest of the industry: there are now two regulators – FDA and CMS – who hold hte keys to success in the pharmaceutical industry.
